Fujian "two standards in one" bloody price

Source: pharmaceutical economic news 2014-08-15 "it's a general mentality to waver between giving up and" bloodletting " It's suggested that enterprises should appropriately participate in bidding in combination with their own reality." limited catalogue, quantity price linkage, only low price is taken This series of words are hitting the nerves of pharmaceutical companies On August 11, the implementation plan for 2014 centralized drug purchase of medical institutions in Fujian Province (Draft for comments) was put on the Internet for comments Under the background of "two standards and one" of basic drugs and non-basic drugs, the document proposes to select nearly 3000 varieties of this round of planned bidding according to the directory of basic drugs, the directory of provincial medical insurance and the directory of new rural cooperative medical system, and set up a regional procurement directory at the same time On the basis of the maximum price limit, the medical institutions of all districts, cities and provinces negotiate and purchase by means of volume purchase and volume price linkage "According to this rule, there are only two ways for enterprises: to" bleed "or to" give up " Li Meng, vice president of Yuanda Pharmaceutical Group's management headquarters, said after reading the plan that the draft was price only in terms of price limit, procurement, bid price, etc In the first half of this year, the bidding attitude of Hunan, Hubei, Hebei and other provinces tends to ease, and the Anhui model is also gradually rectifying the deviation The bidding plan of Fujian province insists on price reduction, which causes controversy The draft pointed out that Fujian province comprehensively considered the level of drug pricing categories, and reasonably determined the maximum price limit of drug centralized procurement in the province by referring to the lowest bid price of national provincial drug centralized procurement officially released since January 1, 2011 In terms of procurement methods, local cross regional joint procurement by districts and cities is encouraged, and it is stipulated that the price limit of drugs with the same generic name and the same level shall not be higher than the median price of the lowest three bid prices of national provincial drug centralized procurement published in the formula since January 1, 2011 Jiang Zhenghan, deputy director of Strategic Development Department of humanwell Pharmaceutical Group, said, "we will participate carefully in the bidding rules guided by price competition." He said that the key markets of competitive products will rationally and moderately participate in the competition, and the non key markets of non competitive products will be mainly wait-and-see, which does not exclude the possibility of "a man of Valor" It is of great concern to the industry that if the price of the bid winning product specification proposed in the draft is significantly higher than the market price or production cost of the same drug of the enterprise, the qualification for winning the bid can be cancelled However, the competitive drugs still use "two envelope" evaluation, but the order is reversed compared with the past "To put it bluntly, it is to arrange the price first, and then determine the shortlisted varieties from the perspective of quality." Li Meng pointed out that according to the current thinking, many high-quality pharmaceutical enterprises, foreign-funded original research pharmaceutical enterprises and other products with higher prices may be eliminated in the price evaluation "The price of foreign brands is well maintained, the impact will be small, and national brands will be hurt As an enterprise, we can only look at it " Jiang Zhenghan also expressed similar views, which in fact distorted the essence of the two envelope system, that is, to pursue lower prices on the basis of quality assurance, and to choose the higher quality products among the lower prices "Excessive pursuit of price rules will make the original intention of quality priority become empty talk." Fierce competition from the catalog list, some exclusive varieties, especially some new drugs, have been rejected In addition, if you want to enter the medical institution, you must first enter the purchase catalogue of the region, otherwise you can only purchase through the record The industry noted that in the last round of bidding in Fujian Province, some products were grouped according to therapeutic efficacy This time, the oral regular release dosage form, oral sustained-release dosage form, and common injection were also grouped in large groups, with fierce competition In the interview, it is a common mindset for enterprises to waver between giving up and not giving up Tian Jialun, vice president of marketing of Xiansheng pharmaceutical, said: "if many enterprises have large non exclusive varieties, they will give up their sales in the region to protect other markets." For example, Jiang Zhenghan said, "in the last round of Fujian bidding, our bid winning rate and bid winning price were not ideal After winning the bid for the exclusive product compound mifepristone tablet, the competitive product mifepristone tablet was abandoned This time the exclusive product is not in the catalogue, the enterprise faces a dilemma At present, the restricted bidding catalogue has begun to show signs in the drug bidding of Anhui Province In June, the national drug symposium held in Qingdao revealed the "scheme for improving the centralized procurement bidding of public medical institutions", which also intends to allow the city as a unit to purchase on the provincial procurement platform in the pilot city of public hospitals Li Meng believes that "the combination of two standards" is a trend to reduce the social cost of enterprise bidding The original intention of medical reform is also to promote the rational use of essential drugs in secondary and tertiary hospitals through compliance with standards " Only Fujian Province has expanded this to all urban areas "On the basis of centralized bidding at the provincial level, it is necessary to focus on solving the problem of interest rent-seeking by replacing regional medical institutions with urban areas for centralized procurement." According to the requirements of Fujian provincial centralized procurement network, the publicity time of the draft for comments is up to August 15, and enterprises are more concerned about whether the new bidding rules will cause chain reaction around "For the varieties that are well done in hospitals, enterprises can appropriately participate in the bidding in combination with their own reality, and the enterprises whose bid price is lower than the cost price will give up the market Otherwise, enterprises either give up supply, which may cause a new round of drug shortage, or reduce operating costs, but this inevitably leads to benefit transfer In my opinion, in the future, it may be more reasonable for the medical insurance department to be the main body of bidding " Li Meng said